Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2017

  • ID: 4384106
  • Report
  • 44 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Antag Therapeutics ApS
  • Carmot Therapeutics Inc
  • Eli Lilly and Company
  • Longevity Biotech Inc
  • Novo Nordisk A/S
  • Sanofi
  • MORE
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2017'; Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR.

The report 'Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Gastrointestinal which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Non-Alcoholic Steatohepatitis (NASH) and Parkinson's Disease.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
  • The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Antag Therapeutics ApS
  • Carmot Therapeutics Inc
  • Eli Lilly and Company
  • Longevity Biotech Inc
  • Novo Nordisk A/S
  • Sanofi
  • MORE
Introduction

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development

Antag Therapeutics ApS

Carmot Therapeutics Inc

Eli Lilly and Company

Hanmi Pharmaceuticals Co Ltd

Longevity Biotech Inc

Novo Nordisk A/S

Sanofi

Zealand Pharma AS

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles

DAJC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBT-6030 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3298176 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NNC-92041706 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize GIPR for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-438335 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GLP1 and GIP Receptors for Non Alcoholic Steatohepatitis, Obesity and Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide 1 for Type 2 Diabetes and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize GIPR for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize GLP-1 and GIP Receptors for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZPDI-70 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZPI-98 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones

Featured News & Press Releases

Sep 15, 2015: Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting

Jun 06, 2015: Presentations on ZP-DI-70, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association’s (ADA) 74th Scientific Sessions

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indication, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by Antag Therapeutics ApS, H2

Pipeline by Carmot Therapeutics Inc, H2

Pipeline by Eli Lilly and Company, H2

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2

Pipeline by Longevity Biotech Inc, H2

Pipeline by Novo Nordisk A/S, H2

Pipeline by Sanofi, H2

Pipeline by Zealand Pharma AS, H2

Dormant Projects, H2

Discontinued Products, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Antag Therapeutics ApS
  • Carmot Therapeutics Inc
  • Eli Lilly and Company
  • Hanmi Pharmaceuticals Co Ltd
  • Longevity Biotech Inc
  • Novo Nordisk A/S
  • Sanofi
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll